文献速递肝病炎症性肠病

患者年龄、性别和炎症性肠病表型与原发性硬化性胆管炎病程相关

Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
PubMed 文献 · Gastroenterology · 2017-03-06

该研究对1980年至2010年间欧洲、北美和澳大利亚37个中心的7121例原发性硬化性胆管炎(PSC)患者进行回顾性结局分析,发现诊断时年龄、性别、胆管亚型和炎症性肠病(IBD)亚型与临床病程显著相关,所供生存估计或可用于评估PSC患者风险水平及筛选临床试验患者。

要点

  • 男性占65.5%,经典或大胆管病变占89.8%,70.0%患者发生IBD;2616例达到主要终点(肝移植或死亡),中位事件时间14.5年。
  • 与溃疡性结肠炎相比,克罗恩病(未校正HR 0.62,P<.001)和无IBD(HR 0.90,P=.03)的肝移植或死亡风险更低。
  • 小胆管型PSC较经典PSC的肝移植或死亡及恶性肿瘤风险更低(HR分别为0.30和0.15,均P<.001)。

核心结论

  • 诊断时年龄、性别、胆管亚型和IBD亚型与PSC临床病程显著相关,所供生存估计或可用于评估PSC患者风险水平及筛选临床试验患者。

研究设计与样本

  • 回顾性结局分析,纳入1980年至2010年间欧洲、北美和澳大利亚37个中心诊断为PSC的患者7121例。
  • 收集性别、临床医生报告的PSC和IBD诊断年龄及日期、IBD和PSC表型、IBD相关手术日期和指征等数据。
  • 主要终点为肝移植或死亡(LTD),次要终点为肝胰胆恶性肿瘤,采用Cox比例风险模型和Kaplan-Meier估计进行时间-事件分析。

主要发现

  • 7121例患者中2616例达到主要终点(中位事件时间14.5年),721例发生肝胰胆恶性肿瘤,最常见的恶性肿瘤为胆管癌(n=594)。
  • 胆管癌发病率随诊断年龄增加:<20岁为1.2/100患者年,21-30岁为6.0/100患者年,31-40岁为9.0/100患者年,41-50岁为14.0/100患者年,51-60岁为15.2/100患者年,>60岁为21.0/100患者年。
  • 全体患者中65.5%为男性,89.8%为经典或大胆管病变,70.0%发生IBD。
  • 以IBD发展为时间依赖协变量,克罗恩病和无IBD(均与溃疡性结肠炎比较)与较低的LTD风险相关(未校正HR 0.62,P<.001;HR 0.90,P=.03),也与较低的恶性肿瘤风险相关(HR 0.68,P=.008;HR 0.77,P=.004)。
  • 小胆管型PSC较经典PSC的LTD或恶性肿瘤风险更低(HR 0.30和HR 0.15,均P<.001);女性较男性的LTD或恶性肿瘤风险更低(HR 0.88,P=.002和HR 0.68,P<.001)。

关键数值与推荐

  • 多变量分析中,小胆管型PSC在男性和女性中均为低风险表型(男性调整HR 0.23,P<.001;女性调整HR 0.48,P=.003)。
  • 溃疡性结肠炎患者较克罗恩病患者肝病进展风险增高(HR 1.56,P<.001),较无IBD患者也增高(HR 1.15,P=.002)。

临床怎么用

  • 原文未据此给出推荐;作者认为所供生存估计或可用于评估PSC患者风险水平及筛选临床试验患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is an orphan hepatobiliary disorder associated with inflammatory bowel disease (IBD). We aimed to estimate the risk of disease progression based on distinct clinical phenotypes in a large international cohort of patients with PSC. METHODS: We performed a retrospective outcome analysis of patients diagnosed with PSC from 1980 through 2010 at 37 centers in Europe, North America, and Australia. For each patient, we collected data on sex, clinician-reported age at and date of PSC and IBD diagnoses, phenotypes of IBD and PSC, and date and indication of IBD-related surgeries. The primary and secondary endpoints were liver transplantation or death (LTD) and hepatopancreatobiliary malignancy, respectively. Cox proportional hazards models were applied to determine the effects of individual covariates on rates of clinical events, with time-to-event analysis ascertained through Kaplan-Meier estimates. RESULTS: Of the 7121 patients in the cohort, 2616 met the primary endpoint (median time to event of 14.5 years) and 721 developed hepatopancreatobiliary malignancy. The most common malignancy was cholangiocarcinoma (n = 594); patients of advanced age at diagnosis had an increased incidence compared with younger patients (incidence rate: 1.2 per 100 patient-years for patients younger than 20 years old, 6.0 per 100 patient-years for patients 21-30 years old, 9.0 per 100 patient-years for patients 31-40 years old, 14.0 per 100 patient-years for patients 41-50 years old, 15.2 per 100 patient-years for patients 51-60 years old, and 21.0 per 100 patient-years for patients older than 60 years). Of all patients with PSC studied, 65.5% were men, 89.8% had classical or large-duct disease, and 70.0% developed IBD at some point. Assessing the development of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis) were associated with a lower risk of LTD (unadjusted hazard ratio [HR], 0.62; P < .001 and HR, 0.90; P = .03, respectively) and malignancy (HR, 0.68; P = .008 and HR, 0.77; P = .004, respectively). Small-duct PSC was associated with a lower risk of LTD or malignancy compared with classic PSC (HR, 0.30 and HR, 0.15, respectively; both P < .001). Female sex was also associated with a lower risk of LTD or malignancy (HR, 0.88; P = .002 and HR, 0.68; P < .001, respectively). In multivariable analyses assessing the primary endpoint, small-duct PSC characterized a low-risk phenotype in both sexes (adjusted HR for men, 0.23; P < .001 and adjusted HR for women, 0.48; P = .003). Conversely, patients with ulcerative colitis had an increased risk of liver disease progression compared with patients with Crohn's disease (HR, 1.56; P < .001) or no IBD (HR, 1.15; P = .002). CONCLUSIONS: In an analysis of data from individual patients with PSC worldwide, we found significant variation in clinical course associated with age at diagnosis, sex, and ductal and IBD subtypes. The survival estimates provided might be used to estimate risk levels for patients with PSC and select patients for clinical trials.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Weismüller TJ, Trivedi PJ, Bergquist A, et al. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017. PMID: 28274849. doi:10.1053/j.gastro.2017.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。